Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resultados 225 a 250 de 368
Resumen de: CN122772976A
0001 本发明涉及生物医药技术领域，尤其是涉及基于PRDX4的PASC相关心血管系统症状风险评估应用。本发明提供了一种以PRDX4为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Resumen de: WO2025176707A1
The present invention relates to an agent that increases Nato3 expression and/or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and/or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and/or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.
Resumen de: WO2025144847A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Resumen de: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Resumen de: CN122772104A
本发明提供了一种抗eMTBR‑tau243蛋白片段的单克隆抗体及其应用和产品，涉及生物技术领域。本发明提供的抗eMTBR‑tau243蛋白片段的单克隆抗体，能够特异性结合tau蛋白片段（aa225‑242），以及包含这个片段的tau蛋白片段（aa1‑256）以及全长tau蛋白（2N4R，aa1‑441），能够用于上述蛋白检测产品的制备。
Resumen de: US20260275418A1
A method is disclosed for detecting schizophrenia, at any stage, which comprises the steps of determining the gene expression of ZNF560 in a biological sample from a subject and comparing it with the ones of a healthy individual as a control sample, wherein the subject of the biological sample is diagnosed as having schizophrenia the gene ZNF560 is overexpressed in the biological sample in comparison to the control. Also disclosed is a kit of parts to diagnose schizophrenia from a biological sample and the use of the kit of parts as a detection agent useful to diagnose schizophrenia, wherein schizophrenia could be at prodromal, acute, residual, or chronic stage.
Resumen de: US20260272976A1
0000 Described herein are methods of monitoring and treating a subject with ALS based on biomarkers.
Resumen de: WO2026192093A1
The present invention provides a digital olfactory data service platform comprising: a digital olfactory data collection system including a multi-channel olfactory sensor array provided to be able to collect digital olfactory data by using various types of odor collection samples collected in a plurality of fields, and a sensing management module provided to be able to manage the odor collection samples and the digital olfactory data; a digital olfactory AI data service system including a digital olfactory data lake, a digital olfactory data service management module, and a digital olfactory data management module, storing olfactory sample-related metadata, digital olfactory data, digital olfactory recognition data, and sensor management data, providing various data management functions stored in the digital olfactory data lake, and providing functions such as product management and subscription management for data services; and an olfactory recognition AI deep learning system including an olfactory recognition deep learning model for performing AI deep learning on the digital olfactory sensor data.
Resumen de: AU2025235500A1
Methods for improving brain function and increasing brain activity by oral administration of choline are provided. Compositions including unit doses of choline sufficient to provide improved brain function and increasing brain activity are also provided. In some embodiments, it includes a method for improving brain function and/or increasing brain efficiency in a subject in need thereof, the methods comprising administering a pharmaceutical composition comprising 550 mg or greater of choline. The increases in brain efficiency are measured by functional Magnetic Resonance Imaging, as compared to placebo, when the subject is performing an N-Back task.
Resumen de: AU2025232230A1
Disclosed herein are chemical probes for unfolded, misfolded or intrinsically disordered proteins, in particular chemical probes having the structure of Formula I or salts thereof, and to the use of the probes for various applications relating to unfolded, misfolded or intrinsically disordered proteins, for example, for diagnosing or prognosing a disease or disorder associated with an unfolded, misfolded or intrinsically disordered protein.
Resumen de: US20260276651A1
0000 The present invention relates to methods for identifying the splicing of RAGE pre-mRNA resulting in the inclusion of exon 9b and/or exclusion of exon 10 in a subject in a subject who has received, or is receiving an antisense oligonucleotide that modulates RAGE pre-mRNA splicing. In one aspect, the present invention provides a method for determining endogenous soluble receptor for advanced glycation end products (RAGE) level in the lung of a subject, the method comprising: determining the presence of endogenous soluble RAGE in a blood sample from a subject who has received or is receiving a treatment administered to their respiratory tract, wherein the treatment increases endogenous soluble RAGE, wherein the level of endogenous soluble RAGE in the blood sample correlates with the endogenous soluble RAGE level in the lung of the subject.
Resumen de: WO2026191421A1
Provided are a dementia diagnosis system and a dementia diagnosis program that are capable of identifying a patient having dementia with high accuracy by a simple and easy test. A dementia diagnosis system (1) has: a measurement unit (51) that continuously measures the acidity/basicity of a body fluid obtained from a subject; a confirmation unit (52) that confirms, for the acidity/basicity continuously measured by the measurement unit (51), an outlier at which the acidity/basicity becomes alkaline and the presence or absence of a change point at which the acidity/basicity persistently shifts to the alkaline side after the outlier is confirmed; and a prediction unit (53) that predicts whether or not the subject has dementia on the basis of the confirmation result of the confirmation unit (52).
Resumen de: WO2026193055A1
Described herein are humanized anti-ApoE antibody molecules, antigen-binding portions thereof, and uses thereof.
Resumen de: WO2026193298A1
Described herein is a method of diagnosing or predicting the risk of cognitive decline in a subject, and/or stratifying the subject according to the risk. The method comprises determining a profile of the subject; and predicting the risk based on the profile, or stratifying the subject to a high risk group or a low risk group based on the predicted risk. The profile comprises blood pressure; and the level of homocysteine (Hyc) in a biological sample from the subject. Also described herein is a method of treating, ameliorating, and/or preventing cognitive decline in the subject based on the prediction of the risk.
Resumen de: WO2026190495A1
The present invention refers to the field of in-vitro neural network stimulation, and particularly to devices that utilize cell cultures on multi-electrode arrays (MEAs) for investigating neuronal activity in research and drug testing applications. The invention consists of a closed loop system wherein a computational model stimulates via the electrodes of a MEA, cultured neurons on top of the MEA in order to produce disease- like activity states. The produced activity feeds back to the computational model, in real or periodic time, producing a hybrid neuronal population that can be used for drug screening. The respective method for the application of the abovementioned system is also disclosed.
Resumen de: WO2026190230A1
The present invention relates to alpha-synuclein antibodies which are useful in diagnostic assays for detecting aggregates, oligomers and fibrillar forms of alpha- synuclein in patient samples. These antibodies enable diagnosis and efficient treatment of alpha-synucleinopathies such as Parkinson's Disease (PD) or Multiple System Atrophy (MSA) patients by assessing and monitoring the pathological alpha-synuclein levels in patients.
Resumen de: WO2026193412A1
Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.
Resumen de: WO2026193026A1
The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).
Resumen de: US20260273141A1
Disclosed herein are methods of inhibiting sterile alpha and TIR motif-containing protein 1 (SARM1) NADase activity in an axon. The methods can also be used to reduce or delay degeneration in an axon, treat or prevent degeneration of an injured axon, enhance fusion of one or more severed axons, and delay degeneration of one or more fused axons, as well as treat a neurological nerve injury or a neurodegenerative disease in a subject in need thereof using a SARM 1 inhibitor.
Resumen de: WO2026189109A1
A high-sensitivity immunoassay method and system. The high-sensitivity immunoassay method for a target protein comprises: capturing the target protein to obtain a solution containing an immune complex; spreading said solution on a detection substrate under the action of a passive driving mechanism; immobilizing the immune complex on at least one surface; and performing detection and calculating the concentration of the immune complex. The immunoassay method uses a consumable structure having a simple structure and low costs, achieving highly sensitive detection of a target protein to be tested.
Resumen de: US20260276627A1
0000 Provided is a method for inhibiting macrophage neurotoxicity, the method comprising increasing expression of Aurora kinase in macrophages, wherein the Aurora kinase includes AURKA, AURKB, or a combination thereof. The expression may be increased by co-culturing the macrophages with neurons such as dorsal root ganglion sensory neurons, hippocampal neurons, dopaminergic neurons, motor neurons, cerebellar granule cells, thalamic neurons, or spinal cord neurons.
Resumen de: US20260276648A1
Methods for identifying tumor tissue and determining a margin of a tumor to be resected in a subject are disclosed within. The methods utilize guanidinoacetic acid (GAA) as a tissue biomarker of malignant brain tumors. The presently disclosed subject matter further relates to methods for providing a diagnosis or prognosis about a cancer in a subject.
Resumen de: WO2025054130A1
The present disclosure relates to enzymes capable of oxidizing betahydroxybutyrate (BHB). In aspects, the enzymes are engineered to optimize BHB activity. Engineered enzymes including amino acid substitutions, truncations, and sequence deletions are further provided. The disclosure further provides for use of enzymes described herein, for example, in test strips, BHB sensors, devices, and systems for detecting and measuring BHB concentration.
Resumen de: US20260276656A1
The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.
Nº publicación: US20260276657A1 17/09/2026
Solicitante:
SIERKS MICHAEL [US]
WILLIAMS STEPHANIE [US]
UNIV ARIZONA STATE [US]
Sierks Michael
Williams Stephanie
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Resumen de: US20260276657A1
Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.
BOPI
Sede Electrónica
